Coronavirus (COVID-19) Collection
Clinical outcomes associated with Mu variant infection during the third epidemic peak of COVID-19 in Colombia
By July 2022, four COVID-19 epidemic peaks and 210 lineages have been registered in Colombia, including several variants of interest and concern (INS, 2022). However, a higher number of cases and deaths occurred during the third epidemic peak, when the B.1.621 (Mu) variant was associated with 50% of the cases in the country (Álvarez-Díaz et al., 2022a). Although several factors in the clinical history of patients with COVID-19 have been associated with a severe or fatal outcome, including comorbidities, age, and smoking history (Zhang et al.Urine sediment findings were milder in patients with COVID-19-associated renal injuries than in those with non-COVID-19-associated renal injuries
Acute renal injury is an important complication of coronavirus disease 2019 (COVID-19). Both COVID-19-specific mechanisms, such as damage to the renal parenchyma by direct infection, and non-specific mechanisms, such as the pre-renal injury factors, have been proposed to be involved in COVID-19-associated renal injuries. In this study, we aimed to elucidate the characteristics of COVID-19-associated renal injuries, focusing mainly on urine sediment findings.Characteristics and Outcomes of COVID-19 in Reproductive-Aged Pregnant and Nonpregnant Women in Osaka, Japan
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, China (Li et al., 2020, Zhou et al., 2020), and rapidly spread worldwide, imposing a major burden on healthcare systems globally. Pregnant women are considered to be at a higher risk of severe morbidity and mortality from other respiratory infections, such as influenza or SARS (Allotey et al., 2020, Blitz et al., 2020, Vintzileos et al., 2020, Xu et al., 2020), than nonpregnant women.Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19
The deleterious impact of the hyperactive immune response triggered by SARS-CoV-2 has been reported since the start of the pandemic (Giamarellos-Bourboulis et al., 2020, Vabret et al., 2020). Therapeutic immunomodulation emerged as a potentially life-saving option for patients with severe COVID-19 (Luis et al., 2021). Available drugs inhibiting the pleiotropic proinflammatory cytokine interleukin 6 (IL-6) rapidly became of particular interest because elevated IL-6 levels seemed to mediate systemic inflammatory responses associated with SARS-CoV-2 infection and the development of acute respiratory distress syndrome (ARDS) and multiorgan failure (McGonagle et al., 2020).Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination
Since the first cases were discovered at the end of 2019, the ongoing COVID-19 pandemic has significantly altered the lives of people around the world. Vaccines to prevent infection from its causative organism, SARS-CoV-2, were developed by the end of 2020 and have now become humanity's hope of regaining normalcy by acquiring protective immunity against COVID-19. However, as vaccines against COVID-19 have been distributed globally at an unprecedented rate, cases of serious adverse events post-vaccination have been accumulating.SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients
The progressive decline in anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels in convalescent patients after primary infection (Achiron et al., 2021; Hartley et al., 2020; Rodda et al., 2021; Sakharkar et al., 2021) raises the possibility of SARS-CoV-2 re-infection, once the humoral immunity is diminished. As a result, attention has been drawn to longstanding immunity against SARS-CoV-2 involving memory B and memory T cells (MBC and MTC, respectively). The presence of specific anti-SARS-CoV-2 MBC and MTC has been demonstrated in convalescent patients (Forthal, 2021; Hartley et al., 2020; Peng et al., 2006; Peng et al., 2020; Rodda et al., 2021; Schwarzkopf et al., 2021; Sekine et al., 2020; Sherina et al., 2021; Thieme et al., 2020).Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similarities
Streptococcus pneumoniae remains the most common cause of community-acquired pneumonia (Van der Poll and Opal, 2009; Johansson et al., 2010). Among pneumonia pathogens, it is the leading cause of hospitalization and death in adults (Roson et al., 2001; Shariatzadeh et al., 2005). Approximately 15–25% of cases of pneumococcal pneumonia are bacteraemic (Said et al., 2013), and bacteraemic pneumococcal community-acquired pneumonia (B-PCAP) has traditionally been considered an invasive form of infection related to higher inflammatory status, worse in-hospital course and shorter long-term survival (Capelastegui et al., 2014; Ishiguro et al., 2016; Ruiz et al., 2019).T-cell receptor repertoires as potential diagnostic markers for patients with COVID-19
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly worldwide (Lai et al., 2020). As of June 20, 2021, SARS-CoV-2 had affected more than 179 060 045 people globally, causing over 3.87 million deaths. In the USA, as many as 34 401 766 individuals had tested positive for COVID-19, and the death toll had reached 617 091 people (Baidu, 2021). The symptoms of COVID-19 include a dry cough, fever, diarrhea, fatigue, pneumonia, and conjunctivitis.Multisystem inflammatory syndrome in adults: A rare sequela of SARS-CoV-2 infection
Most of our understanding of MIS-A is based on various case reports and case series shared by the CDC and published in the medical literature (Bastug et al., 2021; Morris et al., 2020). Here we describe a case of MIS-A in a patient admitted to the Creighton University Medical Center —Bergan Mercy campus in Omaha, Nebraska with clinical presentation and diagnostics suggestive of MIS-A.Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in December 2019 in Wuhan, China, as a pathogen causing severe respiratory infections termed coronavirus disease 2019 (COVID-19) (Zhou et al., 2020). Within a few months, SARS-CoV-2 had spread throughout China and finally resulted in a global pandemic (Ahn et al., 2020). As of March 2021, over 118 million confirmed cases and more than 2.5 million fatalities had been reported worldwide according to WHO statistics (WHO, 2021).Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study
The novel coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has exerted enormous relentless pressures on the global healthcare systems. As of February 4, 2021, over 102 million people were infected with SARS-CoV-2, and more than 2.2 million have died since the start of the pandemic (WHO, 2020). The true number of cases may even exceed the number of diagnosed cases by more than 10-fold (Havers et al., 2020; Stringhini et al., 2020).The use of non-invasive ventilation in COVID-19: A systematic review
The outbreak of COVID-19 began in Wuhan, China, in late December 2019, and has since spread globally, leading to an ongoing pandemic. Among COVID-19 patients, the percentage of patients with severe and critical COVID-19 was reported to be 13.8% and 4.7%, respectively (China CDC, 2020). The most likely cause of death was severe respiratory failure (Berlin et al., 2020). Thus, if means of respiratory support, such as non-invasive ventilation (NIV), can be chosen correctly and implemented in time, the fatality in severe patients could be reduced (Sundaram et al., 2020).
